Nonalcoholic Steatohepatitis Therapeutics Market
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Nonalcoholic</strong> <strong>Steatohepatitis</strong> (NASH)<br />
<strong>Therapeutics</strong> <strong>Market</strong> to Reach<br />
US$20.27 bn by 2025, Elafibranor<br />
Projected to Spur Growth<br />
According to a new market report published by Transparency<br />
<strong>Market</strong> Research “<strong>Nonalcoholic</strong> <strong>Steatohepatitis</strong> <strong>Therapeutics</strong><br />
<strong>Market</strong> - Global Industry Analysis, Size, Share, Growth, Trends,<br />
and Forecast 2015 - 2025”, the nonalcoholic steatohepatitis<br />
(NASH) therapeutics market is anticipated to expand at a CAGR<br />
of 10.7% from 2015 to 2025 to reach US$20.27 bn by 2025.<br />
There are a few key causes of a fatty liver, one of which is nonalcoholic<br />
fatty liver disease. It occurs when excessive alcohol<br />
consumption causes large deposits of fat in the liver. It is one of<br />
the most commonly linked diseases to alcoholism and also one<br />
of the most commonly found liver disorders in developed<br />
economies. Non-alcoholic fatty liver disease (NAFLD) is caused<br />
by reasons linked to metabolic issues and insulin resistance.<br />
Obesity is another factor that can significantly increase the<br />
chances of contracting NAFLD.<br />
According to the National Health and Nutrition Examination<br />
Survey, the rate of NAFLD in the U.S. within 2011 and 2012<br />
was nearly 30%. In cases where NAFLD was not detected in<br />
time and reached higher levels of complications, non-alcoholic
steatohepatitis (NASH) can occur. It is the most extreme form of<br />
non-alcoholic fatty liver disease and is a direct causative factor<br />
for liver cirrhosis.<br />
Browse Full Research Report on <strong>Nonalcoholic</strong><br />
<strong>Steatohepatitis</strong> <strong>Therapeutics</strong> <strong>Market</strong>:<br />
http://www.transparencymarketresearch.com/nonalcoholicsteatohepatitis-market.html<br />
NAFLD by itself can be treated successfully if detected in time.<br />
NASH, on the other hand, needs special care. The global nonalcoholic<br />
steatohepatitis therapeutics market is expected to reach<br />
US$20.2 bn by the end of 2025. It is expanding at a CAGR of<br />
10.70% between 2015 and 2025.<br />
Elafibranor Propels Global NASH <strong>Market</strong><br />
The major segments of the market by drug type include<br />
Saroglitazar, Aramchol, Elafibranor, Obeticholic acid, and<br />
potential drug candidates in phase III. Elafibranor is expected to<br />
lead the market in the near future by being the largest and fastest<br />
growing segment of the global non-alcoholic steatohepatitis<br />
therapeutics market. Elafibranor is currently the most advanced<br />
and most effective drug in this market and is expected to exhibit<br />
the highest CAGR of all the various drug types.
There are no treatments that are specifically used for nonalcoholic<br />
steatohepatitis. Apart from the various drugs used for<br />
the treatment of fatty liver, doctors often suggest the patient to<br />
start losing weight if they are overweight. Other suggestions<br />
given include completely avoiding alcohol, consuming a<br />
balanced diet, and increasing physical activity.<br />
NASH and NAFLD Linked to Obesity<br />
Medical records are pointing to an increasing prevalence of<br />
NAFLD and NASH across the world. However, these issues are<br />
more common in developed economies such as North America.<br />
This is due to the larger percentage of the obese population in<br />
the total population in developed regions than others.<br />
The global non-alcoholic steatohepatitis therapeutics market is,<br />
therefore, developing at a higher rate in countries such as the<br />
U.S., owing to the higher demand for NASH and NAFLD<br />
treatment options. The healthcare industry in these regions is<br />
taking fatty liver complications a lot more seriously.<br />
In the recent past, the number of obese adults and children in the<br />
U.S. have doubled and tripled, respectively. This is a major
issue, as obese patients who suffer from NFALD or NASH are<br />
also likely to suffer from high blood cholesterol and diabetes.<br />
Apart from obesity, patients of glucose intolerance and<br />
dyslipidemia are also prone to suffer from NFALD and NASH.<br />
There is no clear link that points to the reason NFALD occurs,<br />
but it is currently suggested that insulin resistance has a major<br />
role to play in it. In spite of the severity of the disease, patients<br />
are largely asymptomatic until complications arise. Therefore,<br />
the best preventive measure against NFALD and NASH is to<br />
lead a healthy life and moderate alcohol consumption.<br />
The key players in this market that are expected to play a major<br />
role in the market’s immediate future include Tobira<br />
<strong>Therapeutics</strong>, Inc., Conatus Pharmaceuticals, Immuron Ltd.,<br />
Zydus Cadila, Gilead Sciences, Inc., GENFIT SA, Galmed<br />
Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., and<br />
Astazeneca Plc.<br />
Browse Full Press Release on <strong>Nonalcoholic</strong> <strong>Steatohepatitis</strong><br />
<strong>Therapeutics</strong> <strong>Market</strong>:<br />
Press Release
About Us<br />
Transparency <strong>Market</strong> Research (TMR) is a global market<br />
intelligence company providing business information reports<br />
and services. The company’s exclusive blend of quantitative<br />
forecasting and trend analysis provides forward-looking insight<br />
for thousands of decision makers. TMR’s experienced team of<br />
analysts, researchers, and consultants use proprietary data<br />
sources and various tools and techniques to gather and analyze<br />
information.<br />
TMR’s data repository is continuously updated and revised by a<br />
team of research experts so that it always reflects the latest<br />
trends and information. With extensive research and analysis<br />
capabilities, Transparency <strong>Market</strong> Research employs rigorous<br />
primary and secondary research techniques to develop<br />
distinctive data sets and research material for business reports.<br />
Contact Us<br />
Transparency <strong>Market</strong> Research<br />
State Tower,<br />
90 State Street, Suite 700,<br />
Albany NY - 12207<br />
United States<br />
USA - Canada Toll Free: 866-552-3453<br />
Email: sales@transparencymarketresearch.com<br />
Website: http://www.transparencymarketresearch.com